Recce Pharmaceuticals has been awarded a grant of US$2 million (approximately $3 million) by the US Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) for development of burn wound treatments. Recce, an ASX-listed company developing synthetic anti-infectives, said in a statement on Monday morning (AEST) that the grant recognised its RECCE 327 Gel (R327G)…
Orthocell’s strong sales growth Tissue regeneration technology developer Orthocell has announced sales growth across its product portfolio, with total revenue for FY24 of $6.72 million – up 30.40 percent from FY23. Record revenue of $1.84m was achieved for the June 24 Quarter, up 14.41 percent. With Striate+ currently sold in the US, Europe/UK, Australia and…
Quickstep’s new drone order from Carbonix Composites manufacturer Quickstep has announced a significant follow-on order from Australian partner and advanced drone development company Carbonix. The urgent requirement for 40 Volanti airframes and associated non-recurring engineering is the largest yet received from Carbonix for this drone type. Valued at $1.35 million the order is scheduled to…
The federal government’s Research and Development (R&D) tax incentive may have highly restrictive rules and definitions which cut the number of companies eligible for assistance, but for early stage and start up companies it can be a godsend. Available to companies turning over less than $20 million – itself a bone of contention with innovative…
Archer moves biochip graphene sensor to commercial fab Semiconductor company Archer Materials has announced completion of a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. Archer is transferring its first-generation graphene field effect transistor (“gFET”) design to a foundry partner, …
